학술논문

347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up
Document Type
article
Source
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2051-1426